[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Bin Xu\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":68},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100611356","a-prospective-evaluation-of-early-acupuncture-for-immediate-continence-enhancement-after-prostatectomy-100611356",false,"NCT07239518","A Prospective Evaluation of Early Acupuncture for Immediate Continence Enhancement After Prostatectomy","PEACE","Inclusion Criteria:\n\n1. Patients who have undergone radical prostatectomy with a confirmed pathological diagnosis of prostate cancer.\n2. One week post-radical prostatectomy (RP).\n3. Karnofsky Performance Score (KPS) ≥ 60 or ECOG Performance Status 0-1.\n4. Age between 50 and 85 years.\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Pathological results show positive surgical margins.\n2. Previous treatment for post-operative urinary incontinence, such as cystostomy, urethral sphincter reconstruction, or urethral suspension.\n3. Currently or within the last 6 months receiving treatment with principles similar to acupuncture (e.g., electroacupuncture, moxibustion, warm moxibustion).\n4. Active urinary system infection (excluding asymptomatic lower urinary tract infection).\n5. Known severe heart diseases, such as severe arrhythmia, severe heart failure, acute myocarditis, constrictive pericarditis, pericardial tamponade, severe valvular disease, or heart failure.\n6. Known liver damage or potential severe liver disease (ALT or AST \\> 10 times the normal limit).\n7. Known severe renal impairment (eGFR \\\u003C 25mL\u002Fmin\u002F1.73m2), planned or ongoing dialysis, or acute contrast-induced nephropathy at screening.\n8. Known dysfunction of other vital organs or severe primary diseases, such as hematopoietic system diseases.\n9. Known coagulation dysfunction (with typical clinical diagnosis or clear laboratory test results).\n10. Patients with mental illness or cognitive impairment; patients with severe depression, alcohol dependence, or a history of drug abuse.\n11. Urinary incontinence known to be due to other reasons.\n12. According to the investigator's judgment, the patient is not suitable for this study or has a high probability of dropout (e.g., frequent changes in work environment that make follow-up difficult).\n13. Life expectancy ≤ 6 months, as judged by the investigator.\n14. Currently participating in other clinical trials.","MALE","50 Years","85 Years",{"count":20,"type":21},144,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study is being done to see if early acupuncture treatment can help men control their urination better right after their urinary catheter is removed following prostate cancer surgery (radical prostatectomy).\n\nLeaking urine is a very common problem immediately after this surgery, and current treatments often start after the catheter is already out. The researchers in this study believe that starting acupuncture before the catheter is removed might help \"pre-activate\" the nerves and muscles that control urination.\n\nThis is a prospective, multi-center, randomized, placebo-controlled study. The study plans to enroll 144 men who have had prostate cancer surgery. Participants will be randomly assigned (like flipping a coin) into two groups:\n\nTreatment Group (72 participants): Will receive 3 sessions of real electroacupuncture.\n\nControl Group (72 participants): Will receive 3 sessions of sham (placebo\u002Ffake) acupuncture. This involves using a special blunt needle that touches the skin but does not go in, and a machine that looks like it is on but provides no electricity.\n\nThe acupuncture or sham treatment will be given 3 times (on post-operative days 7, 9, and 11). The urinary catheter will be removed for all patients on post-operative day 14. All participants will also receive standard education on pelvic floor muscle exercises.\n\nThe main thing the researchers will measure (the primary endpoint) is the amount of urine leakage (in grams) during a 1-hour pad test, which will be done within the first week after the catheter is removed. Researchers will also check urinary control using questionnaires and other pad tests at 4, 8, 12, and 24 weeks.",[27,28],"Prostate Cancer","Urinary Incontinence","NOT_YET_RECRUITING","2025-11-15",{"date":32,"type":33},"2025-11-20","ACTUAL",{"date":35,"type":21},"2025-12",{"date":37,"type":21},"2027-08",{"name":39,"class":40},"Bin Xu","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":57,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":4},"100605613","phase-2-memantine-hydrochloride-in-prostate-cancer-patients-100605613","NCT07164794","Memantine Hydrochloride in Prostate Cancer Patients","A Prospective Study of Memantine Hydrochloride for the Treatment of Prostate Cancer Patients","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients with metastatic castration-resistant prostate cancer (mCRPC) who have failed one or two prior lines of therapy. Patients with concomitant Alzheimer's disease will be prioritized for enrollment.\n3. Complete clinical baseline data must be available, and the patient must be willing to undergo long-term follow-up.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1\n\nExclusion Criteria:\n\n1. Patients with metastatic prostate cancer at initial diagnosis who have not progressed to mCRPC.\n2. Patients with a concurrent primary malignancy at another site.","18 Years",{"count":50,"type":21},15,[52],"PHASE2","The goal of this clinical trial is to learn if long-term use of memantine hydrochloride can treat, prevent, or correct castration resistance and drug resistance in advanced prostate cancer. The study will enroll male patients aged 18 and older diagnosed with metastatic castration-resistant prostate cancer (mCRPC) who have previously failed first or second-line treatments. The main questions it aims to answer are:\n\nWhat is the progression-free survival (PFS) in patients treated with memantine hydrochloride? What is the disease control rate (DCR) and what is the change in Prostate-Specific Antigen (PSA) levels after treatment?\n\nResearchers will compare outcomes from participants in this single-arm study to an external historical control group of patients who received traditional treatment to see if the addition of memantine hydrochloride improves prognosis.\n\nParticipants will be asked to do the following:\n\nContinue their standard of care treatment, which includes Androgen Deprivation Therapy (ADT) and a novel endocrine therapy.\n\nTake the study drug, memantine hydrochloride, with the dose gradually increasing over the first three weeks to a maintenance dose.\n\nAttend regular follow-up appointments for blood tests to check PSA levels and undergo imaging scans to monitor the disease status. These follow-ups will occur one month after starting the drug and every three months thereafter.",[55,27,56],"Metastatic Castration-resistant Prostate Cancer (mCRPC)","Neuroendocrine Prostate Cancer (NEPC)",[58,59,60],"Memantine","mCRPC","Prospective Study",{"date":62,"type":33},"2025-11-19",{"date":64,"type":21},"2025-11",{"date":66,"type":21},"2028-06",{"name":39,"class":40},""]